Welcome to our dedicated page for Afya SEC filings (Ticker: AFYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Afya Limited (AFYA) is a foreign private issuer that reports to the U.S. Securities and Exchange Commission primarily through Form 20‑F and Form 6‑K. This SEC filings page centralizes access to those documents, which provide detailed information on the company’s operations as a medical education group and medical practice solutions provider in Brazil.
Afya’s Form 20‑F annual report contains audited financial statements and extensive narrative disclosures on its three reportable segments: Undergraduate, Continuing Education and Medical Practice Solutions. Investors can review segment definitions, revenue composition, key operational metrics and risk factors related to its physician‑centric ecosystem and Brazilian regulatory environment.
Throughout the year, Afya files multiple Form 6‑K reports. These include unaudited interim condensed consolidated financial statements, press releases announcing quarterly and half‑year financial results, and disclosures on specific corporate events. Examples documented in recent 6‑Ks include new share repurchase programs for Class A common shares, issuance of commercial notes by Afya Participações S.A., repayment of debentures, repurchase and cancellation of Series A perpetual convertible preferred shares, changes to the board of directors, results of the annual general meeting and the engagement of a new independent registered public accounting firm.
For investors analyzing AFYA, these filings are key sources for understanding revenue trends, adjusted EBITDA, net income, capital structure decisions and governance developments. They also provide context on Afya’s medical school seat authorizations and other regulatory milestones in Brazil’s higher education sector.
On Stock Titan, Afya’s SEC filings are updated in line with EDGAR submissions and can be paired with AI‑powered summaries that explain the main points of lengthy documents. Users can quickly identify which filings relate to financial results, capital markets transactions, governance changes or other material events, and then drill down into the full text when deeper analysis is required.
Afya Limited delivered solid results for the three-month period ended March 31, 2026, with revenue of R$1,012,712 thousand, up from R$936,360 thousand a year earlier. Growth was driven mainly by higher tuition fees across its undergraduate and continuing education operations.
Operating income reached R$393,600 thousand and net income was R$261,763 thousand, compared with R$257,036 thousand in the prior-year period. Basic earnings per share rose to R$2.88, while diluted earnings per share were R$2.85.
Afya generated strong net cash from operating activities of R$466,796 thousand and ended the period with cash and cash equivalents of R$1,332,866 thousand. The company continued to return capital, approving dividends of R$307,377 thousand and repurchasing treasury shares for R$69,511 thousand, while maintaining loans and financing of R$2,124,512 thousand.
Afya Limited delivered steady growth in the first quarter of 2026, with revenue reaching R$1,012.7 million, up 8.2% from a year earlier, driven mainly by higher medical course prices, more non-medical undergrad students, the FUNIC acquisition and expansion in Continuing Education.
Adjusted EBITDA rose 4.0% to R$511.4 million, while the margin slipped to 50.5% from 52.5% as Afya increased spending in Continuing Education and Medical Practice Solutions to support its investment cycle. Net income grew 1.8% to R$261.8 million, and basic EPS improved to R$2.88.
Cash and cash equivalents climbed to R$1,332.9 million, and net debt excluding IFRS 16 fell to R$1,151.3 million, aided by strong operating cash flow and despite acquisitions, dividends and share repurchases. Afya reaffirmed its 2026 guidance, including revenue between R$3.95–4.10 billion and Adjusted EBITDA of R$1.7–1.8 billion, and highlighted a R$307.4 million dividend and ongoing buybacks.
Afya Ltd executive Anibal Jose Grifo de Sousa, V.P. Legal, Compliance & Government Relations, exercised stock options covering 19,000 Class A common shares at $11.83 per share. This option exercise converted derivative holdings into common stock and did not involve any open-market sale.
Following the transaction, he directly owns 50,000 Class A common shares. The related stock option for 19,000 shares, originally exercisable beginning on May 1, 2025 and expiring on May 1, 2028, now shows zero derivative shares remaining in this award.
Afya Ltd Vice President Junior Lelio de Souza exercised stock options to acquire 66,000 Class A common shares on April 22, 2026. The options had an exercise price of $11.83 per share. After these transactions, he directly holds 66,000 Class A common shares and 6,000 stock options.
Afya Ltd Controller Welder Ferreira Santos reported an open-market sale of 3,325 Class A common shares. The shares were sold at an average price of $15.90 per share. After this transaction, the insider directly holds 35,000 Class A common shares, indicating the sale represents a relatively small portion of their overall position.
Afya Ltd executive Anibal Jose Grifo de Sousa, VP Legal, Compliance and Government Relations, reported open-market sales of Class A common shares. On April 13, 2026, he sold a total of 14,000 shares in three transactions priced between $15.35 and $15.50 per share. Following these sales, he directly holds 31,000 Class A common shares.
Afya Ltd Vice President Junior Lelio de Souza reported an open-market sale of Class A common shares. On April 9, 2026, he sold 16,279 Class A Common Shares at a price of $14.53 per share, leaving him with 0 shares of this security held directly after the transaction.
Afya Ltd Chief Financial Officer sells shares in open-market trade. CFO Luis Andre Carpintero Blanco sold 10,000 Class A common shares of Afya Ltd in an open-market transaction at $15.20 per share. After this sale, he directly holds 51,103 Class A common shares.
Afya Ltd Vice President Junior Lelio de Souza sold Class A shares in an open-market trade. He sold 26,753 Class A common shares at $14.95 per share and now directly holds 16,279 shares. This was a straightforward sale of existing stock, with no derivatives reported.
Afya Ltd executive Anibal Jose Grifo de Sousa, VP Legal, Compliance and Government Relations, conducted an open-market sale of 5,000 Class A Common Shares on April 7, 2026 at $15.20 per share. After this transaction, he continues to hold 45,000 Class A Common Shares directly, indicating he retains a substantial personal stake in the company despite trimming his position.